Calcium channel blockers and hypertension: 2. Safety issues

Hospital Practice

Volumn 31, Issue 12, 1996, Pages 93-104

  Epstein, Murray ^a,b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; NIFEDIPINE; NIMODIPINE; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; REVIEW; SINGLE BLIND PROCEDURE;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; SAFETY;

EID: 0030447201     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.1080/21548331.1996.11443394     Document Type: Article

References (17)

1. Abascal VM et al: Calcium channel blocker use is not associated with increased mortality (abstract). Circulation 94: 3383, 1996
2. Bigger JT Jr et al: Effect of diltiazem on cardiac rate and rhythm after myocardial infarction. Am J Cardiol 65:539, 1990
3. Billman GE: The antiarrhythmic effects of calcium antagonists. In Calcium Antagonists in Clinical Medicine, Epstein M (Ed). Hanley & Belfus, Philadelphia, 1992, pp 183-212
4. Epstein M: Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 155:2150, 1995
5. Epstein M: Calcium antagonists in the management of hypertension. In Calcium Antagonists in Clinical Medicine, Epstein M (Ed). Hanley & Belfus, Philadelphia, 1992, pp 213-230
6. Frohlich ED et al: Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol 68: 1346, 1991
7. Held PH, Yusuf S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. Br Med J 299:1187, 1989
8. Kleinbloesem CH et al: Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 41:26, 1987
9. Kloner RA: Nifedipine in ischemic heart disease (editorial). Circulation 92:1074, 1995
10. Kuglyama K et al: Effects of propranolol and nifedipine on exercise-induced attack in patients variant angina: Assessment by exercise thallium-201 myocardial scintigraphy with quantitative rotational tomography. Circulation 74:374, 1986
11. Lansheng G et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 14:1237, 1996
12. Malacoff RF et al: Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation 65 (suppl I):I, 1982
13. Melandri G et al: Myocardial metabolic and hemodynamic effects of a sustained intravenous infusion of nifedipine with and without metoprolol in patients with unstable angina. Am Heart J 121:44, 1991
14. Morris AD, Meredith PA, Reid JL: Pharmacokinetics of calcium antagonists: Implications for therapy. In Calcium Antagonists in Clinical Medicine, Epstein M (Ed). Hanley & Belfus, Philadelphia, 1992, pp 49-67
15. Neaton JD et al: Treatment of Mild Hypertension Study: Final results. JAMA 270:713, 1993
16. Opie LH, Messerli FH: Nifedipine and mortality. Grave defects in the dossier (editorial). Circulation 92:1068, 1995
17. Packer M et al: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Eng J Med 335:1107, 1996